Gilead Cancer Drug Deal Might Change The Case For Investing In Vir Biotechnology (VIR)

Simply Wall St.10-20

Vir Biotechnology announced a collaboration and license agreement with Gilead that gives Gilead exclusive rights to develop and commercialize up to three PRO-XTEN dual-masked T-cell engagers for solid...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676169874?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-20 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676169874","market":"sg","top_or_hot":-1,"title":"Gilead Cancer Drug Deal Might Change The Case For Investing In Vir Biotechnology (VIR)","media":"Simply Wall St.","content":"<div>\n<p>Vir Biotechnology announced a collaboration and license agreement with Gilead that gives Gilead exclusive rights to develop and commercialize up to three PRO-XTEN dual-masked T-cell engagers for solid...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/gilead-cancer-drug-deal-might-change-the-case-for-investing\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Cancer Drug Deal Might Change The Case For Investing In Vir Biotechnology (VIR)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Cancer Drug Deal Might Change The Case For Investing In Vir Biotechnology (VIR)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-20 19:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/gilead-cancer-drug-deal-might-change-the-case-for-investing><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vir Biotechnology announced a collaboration and license agreement with Gilead that gives Gilead exclusive rights to develop and commercialize up to three PRO-XTEN dual-masked T-cell engagers for solid...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/gilead-cancer-drug-deal-might-change-the-case-for-investing\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/gilead-cancer-drug-deal-might-change-the-case-for-investing","article_id":"2676169874","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/gilead-cancer-drug-deal-might-change-the-case-for-investing","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676169874","pubTimestamp":1792495980,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vir Biotechnology announced a collaboration and license agreement with Gilead that gives Gilead exclusive rights to develop and commercialize up to three PRO-XTEN dual-masked T-cell engagers for solid tumors, with Vir handling early discovery and design and receiving a mix of cash, equity and milestone-based payments.\nThe deal brings Vir Biotechnology up to $135 million in upfront and near-term milestones plus potential longer term payments and royalties, which directly ties its PRO-XTEN...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4535":"淡马锡持仓","VIR":"Vir Biotechnology, Inc."},"translate_title":"吉利德癌症药物交易可能会改变投资 Vir Biotechnology (VIR) 的情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1.5},"content_text":"Vir Biotechnology announced a collaboration and license agreement with Gilead that gives Gilead exclusive rights to develop and commercialize up to three PRO-XTEN dual-masked T-cell engagers for solid tumors, with Vir handling early discovery and design and receiving a mix of cash, equity and milestone-based payments. The deal brings Vir Biotechnology up to $135 million in upfront and near-term milestones plus potential longer term payments and royalties, which directly ties its PRO-XTEN oncology platform to a large partner and helps fund clinical programs without relying solely on its own balance sheet. We will now look at how Vir Biotechnology's Gilead funded T-cell engager collaboration could influence the investment narrative around its oncology expansion.  Scan Vir Biotechnology's oncology pivot against a curated field of peers by reviewing our 33 healthcare AI stocks that are also pushing the boundaries of immuno-oncology and targeted therapies. AdvertisementVir Biotechnology Investment Narrative Recap To own Vir Biotechnology, you need to believe its infectious disease base and PRO-XTEN oncology platform can support a long runway of partnered assets, even with current losses and forecast earnings pressure. The Gilead tie-up brings cash, equity and milestones that can help fund this shift without leaning entirely on new equity raises. In the near term, ECLIPSE in hepatitis delta and early oncology readouts remain key swing factors for sentiment. The Gilead agreement appears helpful for funding and validation; however, it does not remove the core risk that unproven T-cell engagers and other programs may produce uneven clinical outcomes and prolonged unprofitability. The FDA Fast Track designation for VIR-5500 is tightly linked to this story. It shows regulators are engaging with Vir Biotechnology's first PRO-XTEN T-cell engager in prostate cancer and that the platform is already in human studies, with a Phase 1 trial under way across several mCRPC and mHSPC cohorts. If VIR-5500 continues to show acceptable safety and early anti-tumor activity, that readthrough could matter for the newer Gilead-partnered solid tumor T-cell engagers. Any setback for VIR-5500, whether clinical or regulatory, would likely weigh on confidence in PRO-XTEN as a growth pillar and increase focus on Vir's cash burn and dependence on partners. Vir Biotechnology's setup assumes revenue of US$171.2 million and earnings of US$32.5 million by 2029. That profile is based on analysts modelling 37.8% yearly revenue growth and an earnings swing of about US$475.2 million from a current loss of US$442.7 million. Uncover why Vir Biotechnology's fair value indicates a 111% potential upside to its current price that could narrow quickly. NasdaqGS:VIR 1-Year Stock Price Chart Exploring Other Perspectives Some of the most optimistic analysts frame Vir Biotechnology very differently. They lean into the hepatitis delta opportunity and, even before this Gilead news, were modelling revenue of about US$355.8 million and earnings of roughly US$57.8 million by 2029. That is a far richer story than consensus. It could also shift again as you weigh fresh information. Explore another Vir Biotechnology fair value estimate, including one that suggests as much as 111% upside from the current price. Form Your Own Verdict Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Vir Biotechnology research is our analysis highlighting 3 important warning signs that could impact your investment decision. See our latest analysis for Vir Biotechnology. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Vir Biotechnology's overall financial health at a glance.  Looking For More Investment Ideas Beyond Vir Biotechnology? If the Vir Biotechnology story has sharpened your thinking but you want a broader hunting ground, the Simply Wall St Screener can help you surface other opportunities that fit your style and risk appetite.  If you prize resilient balance sheets and want less financial fragility in your portfolio, start with this curated list of solid balance sheet and fundamentals (25 results) that keep debt and liquidity in tighter check. For readers who prefer value-led ideas with stronger fundamentals, filter the market using a focused 20 high quality undiscovered gems that often sit off the usual radar. If lower volatility and steadier business profiles appeal more than high-octane stories, narrow your search to a concentrated 32 resilient stocks with low risk scores aligned with a more defensive approach.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676169874","isCrawlerRequest":true}